Novartis announced that the US Food and Drug Administration (FDA) has granted Priority Review status to Scemblix® (asciminib) for the treatment of newly diagnosed adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP). The FDA’s Priority…
Allergan Aesthetics is excited to announce the return of JUVÉDERM® Day on Wednesday, August 21. Following the success of its inaugural event, JUVÉDERM® Day offers limited-time deals, savings, and exclusive promotions through Allē, Allergan Aesthetics’ loyalty rewards program. “JUVÉDERM® Day…
Roche announced today the completion of its acquisition of LumiraDx’s Point-of-Care technology, following the necessary antitrust and regulatory approvals. The acquisition will see Roche integrate LumiraDx’s multi-assay point-of-care platform, along with its R&D, operational, and commercial sites, into Roche’s global…
Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion on updating the Wegovy® (semaglutide 2.4 mg) label. This update reflects data from the SELECT cardiovascular outcomes…
MSD, known as Merck outside the United States and Canada, has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of KEYTRUDA, Merck’s anti-PD-1 therapy. This recommendation…
Verastem Oncology, a biopharmaceutical company focused on developing new cancer treatments, announced its intention to offer and sell shares of common stock and accompanying warrants to purchase common stock. The offering will also include pre-funded warrants, which can be purchased…
Verastem Oncology, a biopharmaceutical company focused on cancer treatments, announced the pricing of an underwritten public offering. The offering includes 13,333,334 shares of common stock and accompanying warrants to purchase up to 13,333,334 shares at $3.00 per share and warrant.…
Hims & Hers Health, a leading health and wellness platform, has announced the appointment of Kåre Schultz to its Board of Directors. Schultz, known for his extensive global expertise in healthcare and pharmaceuticals, brings decades of experience from his roles…
Lario Therapeutics Secures $6M Grant from Michael J. Fox Foundation for Parkinson’s Research Lario Therapeutics, a biopharmaceutical company focused on pioneering precision medicines for neurological and epileptic disorders, has announced it has been awarded a $6 million USD grant from…
AIDS Healthcare Foundation (AHF) will hold an in-person and virtual press conference at the AHF booth (#111) during the 2024 International AIDS Conference (AIDS 2024) on Tuesday, July 23, at 13:15 CEST (7:15 a.m. US EDT) in Munich, Germany, at…
Rusan Pharma, an India-based pharmaceutical company specializing in addiction treatment and pain management, recently announced that the United States Food and Drug Administration (USFDA) has granted Good Manufacturing Practice (GMP) approval for its Active Pharmaceutical Ingredient (API) facility in Ankleshwar,…
Ionis Pharmaceuticals today revealed that it has finalized enrollment in its pivotal trial evaluating zilganersen (ION373), an investigational RNA-targeted therapy aimed at treating children and adults with Alexander disease (AxD), a rare, progressive, and ultimately fatal neurological disorder. The trial’s…